Literature DB >> 17519393

Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia?

Steven R Laviolette1.   

Abstract

The neural regulation of emotional perception, learning, and memory is essential for normal behavioral and cognitive functioning. Many of the symptoms displayed by individuals with schizophrenia may arise from fundamental disturbances in the ability to accurately process emotionally salient sensory information. The neurotransmitter dopamine (DA) and its ability to modulate neural regions involved in emotional learning, perception, and memory formation has received considerable research attention as a potential final common pathway to account for the aberrant emotional regulation and psychosis present in the schizophrenic syndrome. Evidence from both human neuroimaging studies and animal-based research using neurodevelopmental, behavioral, and electrophysiological techniques have implicated the mesocorticolimbic DA circuit as a crucial system for the encoding and expression of emotionally salient learning and memory formation. While many theories have examined the cortical-subcortical interactions between prefrontal cortical regions and subcortical DA substrates, many questions remain as to how DA may control emotional perception and learning and how disturbances linked to DA abnormalities may underlie the disturbed emotional processing in schizophrenia. Beyond the mesolimbic DA system, increasing evidence points to the amygdala-prefrontal cortical circuit as an important processor of emotionally salient information and how neurodevelopmental perturbances within this circuitry may lead to dysregulation of DAergic modulation of emotional processing and learning along this cortical-subcortical emotional processing circuit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17519393      PMCID: PMC2632330          DOI: 10.1093/schbul/sbm048

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  88 in total

1.  Arousal dissociates amygdala and hippocampal fear responses: evidence from simultaneous fMRI and skin conductance recording.

Authors:  L M Williams; M L Phillips; M J Brammer; D Skerrett; J Lagopoulos; C Rennie; H Bahramali; G Olivieri; A S David; A Peduto; E Gordon
Journal:  Neuroimage       Date:  2001-11       Impact factor: 6.556

2.  Electrical stimulation of medial prefrontal cortex reduces conditioned fear in a temporally specific manner.

Authors:  M R Milad; I Vidal-Gonzalez; G J Quirk
Journal:  Behav Neurosci       Date:  2004-04       Impact factor: 1.912

3.  Single unit response of noradrenergic, serotonergic and dopaminergic neurons in freely moving cats to simple sensory stimuli.

Authors:  K Rasmussen; R E Strecker; B L Jacobs
Journal:  Brain Res       Date:  1986-03-26       Impact factor: 3.252

Review 4.  The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function.

Authors:  A A Grace
Journal:  Drug Alcohol Depend       Date:  1995-02       Impact factor: 4.492

5.  Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study.

Authors:  S K Goldsmith; R M Shapiro; J N Joyce
Journal:  Arch Gen Psychiatry       Date:  1997-07

6.  Neurons in medial prefrontal cortex signal memory for fear extinction.

Authors:  Mohammed R Milad; Gregory J Quirk
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

7.  Dopamine-mediated modulation of odour-evoked amygdala potentials during pavlovian conditioning.

Authors:  J Amiel Rosenkranz; Anthony A Grace
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

8.  Regional brain metabolic activation during craving elicited by recall of previous drug experiences.

Authors:  G J Wang; N D Volkow; J S Fowler; P Cervany; R J Hitzemann; N R Pappas; C T Wong; C Felder
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

9.  Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.

Authors:  D S Janowsky; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-03

Review 10.  Deficits in facial-affect recognition and schizophrenia.

Authors:  R L Morrison; A S Bellack; K T Mueser
Journal:  Schizophr Bull       Date:  1988       Impact factor: 9.306

View more
  52 in total

Review 1.  Neuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment?

Authors:  Abdalla Bowirrat; Thomas J H Chen; Marlene Oscar-Berman; Margaret Madigan; Amanda Lh Chen; John A Bailey; Eric R Braverman; Mallory Kerner; John Giordano; Siobhan Morse; B William Downs; Roger L Waite; Frank Fornari; Zaher Armaly; Kenneth Blum
Journal:  Mol Neurobiol       Date:  2012-02-28       Impact factor: 5.590

Review 2.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

3.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

4.  A comparison of regional brain volumes and white matter connectivity in subjects with stimulant induced psychosis versus schizophrenia.

Authors:  Peter D Alexander; Kristina M Gicas; Alex Cheng; Donna J Lang; Ric M Procyshyn; Alexandra T Vertinsky; William J Panenka; Allen E Thornton; Alexander Rauscher; Jamie Y X Wong; Tasha Chan; Andrea A Jones; F Vila-Rodriguez; William G Honer; Alasdair M Barr
Journal:  Psychopharmacology (Berl)       Date:  2019-06-22       Impact factor: 4.530

5.  The final common pathway of schizophrenia.

Authors:  Peter Williamson
Journal:  Schizophr Bull       Date:  2007-05-24       Impact factor: 9.306

6.  Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Teresa Popolizio; Paolo Taurisano; Grazia Caforio; Raffaella Romano; Annabella Di Giorgio; Fabio Sambataro; Valeria Rubino; Valeria Latorre; Luciana Lo Bianco; Leonardo Fazio; Marcello Nardini; Daniel R Weinberger; Alessandro Bertolino
Journal:  Psychiatry Res       Date:  2009-05-09       Impact factor: 3.222

7.  The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults.

Authors:  Stefan Ehrlich; Eric M Morrow; Joshua L Roffman; Stuart R Wallace; Melissa Naylor; H Jeremy Bockholt; Antonia Lundquist; Anastasia Yendiki; Beng-Choon Ho; Tonya White; Dara S Manoach; Vincent P Clark; Vince D Calhoun; Randy L Gollub; Daphne J Holt
Journal:  Neuroimage       Date:  2009-12-21       Impact factor: 6.556

8.  Basal microRNA expression patterns in reward circuitry of selectively bred high-responder and low-responder rats vary by brain region and genotype.

Authors:  David E Hamilton; Christopher L Cooke; Bradley S Carter; Huda Akil; Stanley J Watson; Robert C Thompson
Journal:  Physiol Genomics       Date:  2014-02-25       Impact factor: 3.107

9.  Associations between psychotic-like symptoms and inattention/hyperactivity symptoms.

Authors:  Tuula Marketta Hurtig; Anja Taanila; Juha Veijola; Hanna Ebeling; Pirjo Mäki; Jouko Miettunen; Marika Kaakinen; Matti Joukamaa; Sebastian Therman; Markus Heinimaa; Marjo-Riitta Järvelin; Irma Moilanen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-11-12       Impact factor: 4.328

Review 10.  The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.